BMRA (Biomerica) EBITDA: $-4.94 Mil (TTM As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BMRA Biomerica Inc BMRA
50 GF Score
Price $1.49
GF Value $2.18
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Biomerica EBITDA?

Biomerica BMRA -6.28% 50 EBITDA is $-4.94 Mil as of Feb. 2026. GuruFocus rates BMRA with a GF Score™ of 50/100 and a GF Value™ of $2.18 (Possible Value Trap). The stock has 5 warning signs investors should review.

Biomerica's EBITDA for the three months ended in Feb. 2026 was $-1.19 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Feb. 2026 was $-4.94 Mil.

During the past 3 years, the average EBITDA Growth Rate was -6.30% per year. During the past 5 years, the average EBITDA Growth Rate was -11.30% per year. During the past 10 years, the average EBITDA Growth Rate was -34.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Biomerica was 148.40% per year. The lowest was -78.20% per year. And the median was -0.50% per year.

Biomerica's EBITDA per Share for the three months ended in Feb. 2026 was $-0.40. Its EBITDA per share for the trailing twelve months (TTM) ended in Feb. 2026 was $-1.88.

During the past 3 years, the average EBITDA per Share Growth Rate was 6.10% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 1.00% per year. During the past 10 years, the average EBITDA per Share Growth Rate was -22.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Biomerica was 139.00% per year. The lowest was -59.60% per year. And the median was 5.45% per year.

Biomerica  (NAS:BMRA) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Biomerica EBITDA Related Terms


Biomerica EBITDA Historical Data

* Premium members only.

The historical data trend for Biomerica's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomerica EBITDA Chart

Biomerica Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.06 -3.94 -6.87 -5.99 -4.74

Biomerica Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.11 -1.46 -1.02 -1.27 -1.19

BMRA vs WOK, ALURD, ITOC: EBITDA Comparison

For the Medical Devices subindustry, Biomerica's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomerica EV-to-EBITDA vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Biomerica's EV-to-EBITDA falls into.


BMRA
50GF Score
Biomerica Inc BMRA
EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Biomerica's EBITDA for the fiscal year that ended in May. 2025 is calculated as

Biomerica's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in May. 2025, Biomerica's EBITDA was $-4.74 Mil.

Biomerica's EBITDA for the quarter that ended in Feb. 2026 is calculated as

Biomerica's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Feb. 2026, Biomerica's EBITDA was $-1.19 Mil.

EBITDA for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of $-4.94 Mil mean?
Biomerica (BMRA) has a EBITDA of $-4.94 Mil as of Feb. 2026. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Biomerica.
Is Biomerica's EBITDA too high?
Biomerica's current EBITDA is $-4.94 Mil. Overall, Biomerica has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biomerica's EBITDA compare to WOK and ALURD?
Biomerica's EBITDA of $-4.94 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Medical Devices & Instruments company?
A good EBITDA depends on the Medical Devices & Instruments industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Biomerica. Biomerica's current EBITDA is $-4.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomerica stock overvalued right now?
Based on GuruFocus' analysis, Biomerica (BMRA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.18, compared to a current price of $1.49 — trading 31.7% below its estimated fair value. The current EBITDA is $-4.94 Mil. Biomerica's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Biomerica (BMRA), the current EBITDA is $-4.94 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biomerica (BMRA) Overvalued in 2026?

Based on GuruFocus' analysis, Biomerica stock appears to be undervalued. The current stock price of $1.49 is trading 31.7% below its estimated GF Value™ of $2.18. GuruFocus considers Biomerica to be Possible Value Trap.

Key valuation signals for BMRA:

  • EBITDA: $-4.94 Mil
  • GF Value™: $2.18 vs. price of $1.49 (31.7% below fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the BMRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biomerica Business Description

Address 17571 Von Karman Avenue, Irvine, CA, USA, 92614
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
50GF Score

Get the complete analysis for BMRA

EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.49
Price
$2.18
GF Value